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Objectives The aim of this study was to demonstrate the feasibility of combining the novel heart valve replacement technol-
ogies of: 1) tissue engineering; and 2) minimally-invasive implantation based on autologous cells and composite
self-expandable biodegradable biomaterials.
Background Minimally-invasive valve replacement procedures are rapidly evolving as alternative treatment option for patients
with valvular heart disease. However, currently used valve substitutes are bioprosthetic and as such have limited
durability. To overcome this limitation, tissue engineering technologies provide living autologous valve replace-
ments with regeneration and growth potential.
Methods Trileaflet heart valves fabricated from biodegradable synthetic scaffolds, integrated in self-expanding stents and
seeded with autologous vascular or stem cells (bone marrow and peripheral blood), were generated in vitro us-
ing dynamic bioreactors. Subsequently, the tissue engineered heart valves (TEHV) were minimally-invasively im-
planted as pulmonary valve replacements in sheep. In vivo functionality was assessed by echocardiography and
angiography up to 8 weeks. The tissue composition of explanted TEHV and corresponding control valves was
analyzed.
Results The transapical implantations were successful in all animals. The TEHV demonstrated in vivo functionality with
mobile but thickened leaflets. Histology revealed layered neotissues with endothelialized surfaces. Quantitative
extracellular matrix analysis at 8 weeks showed higher values for deoxyribonucleic acid, collagen, and glycos-
aminoglycans compared to native valves. Mechanical profiles demonstrated sufficient tissue strength, but less
pliability independent of the cell source.
Conclusions This study demonstrates the principal feasibility of merging tissue engineering and minimally-invasive valve re-
placement technologies. Using adult stem cells is successful, enabling minimally-invasive cell harvest. Thus, this
new technology may enable a valid alternative to current bioprosthetic devices. (J Am Coll Cardiol 2010;56:
510–20) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.024v
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dly evolving as alternative treatment option for patients
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August 3, 2010:510–20 Minimally-Invasive Autologous Tissue Engineered Heart Valveechniques, such as the transapical approach, have been de-
cribed as safe and successful procedures particularly for pa-
ients with more advanced atherosclerosis and/or complex
eart valve pathologies (2,3). However, the currently available
alve substitutes for minimally-invasive replacement proce-
ures are bioprosthetic and as such will be associated with
alcification and progressive dysfunctional degeneration similar
o that of conventional nonviable tissue valves (glutaraldehyde
xed, and so forth). That suggests their primary clinical
pplication in elderly patients (2).
Autologous, viable valve substitutes with regeneration
otential would overcome the limitations of today’s valve
rostheses and enable the application of minimally-invasive
reatment modalities also in younger patients (4,5). In
ecent years, tissue engineering techniques have been devel-
ped on the basis of decellularized allografts or rapidly
egrading synthetic scaffold materials and autologous cells,
iming at living heart valve replacements with regeneration
otential. Feasibility and functionality of such tissue engi-
eered heart valves (TEHVs) implanted by conventional
urgical procedures have been demonstrated by in vitro as
ell as in vivo experiments and initial clinical trials (6–12).
herefore, TEHV implanted by a minimally-invasive tech-
ique could become a viable autologous alternative to
ioprosthetic valve replacements. A clinically relevant heart
alve tissue engineering concept would ideally comprise
oth minimally-invasive techniques for cell harvest and
alve implantation. Here, the first in vitro and in vivo
xperiences in an animal model toward a “complete”
inimally-invasive heart valve tissue engineering approach
Figure 1 Macroscopic Appearance of TEHV Before Implantation
Macroscopic picture of autologous tissue engineered heart valve (TEHV) based on
vascular-derived cells integrated into a self-expanding nitinol stent, (A) distal viewased on rapidly degrading com-
osite scaffolds and autologous
ascular and adult stem cells are
resented.
ethods
his comprehensive study com-
rises 2 sequential experimental
etups. In a first set of experiments
study A), the principal feasibility
f creating in vitro TEHV, which
an be implanted by transapical,
inimally-invasive delivery with
dequate in vivo functionality, was
nvestigated. A second set of ex-
eriments (study B) was focused on the feasibility to utilize
utologous stem cells (bone marrow, peripheral blood) as a less
nvasive, multipotent alternative cell source. Both concepts
ere tested in sheep, representing the most used animal model
or heart valve prostheses.
xperimental study A: merging TEHV and minimally-
nvasive implantation technologies, in vitro and in vivo
easibility. Valve replacements (n  16) for minimally-
nvasive implantation technologies were manufactured by inte-
rating TEHV into self-expandable stents (Figs. 1A and 1B).
he TEHV were cultured in vitro using dynamic in vitro
ulture protocols. In vivo performance up to 8 weeks of
EHV was evaluated after transapical implantation in
heep (n  6) in pulmonary position. Next to each im-
Abbreviations
and Acronyms
DNA  deoxyribonucleic
acid
eNOS  endothelial nitric
oxide synthase
GAG  glycosaminoglycans
OD  outer diameter
SMA  smooth muscle
actin
TEHV  tissue engineered
heart valve
UTS  ultimate tensile
strength
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Minimally-Invasive Autologous Tissue Engineered Heart Valve August 3, 2010:510–20lanted TEHV, an additional valve was engineered for each
nimal to serve as a control valve (n  6). The transapical
elivery procedure required crimping of the TEHV to
ecrease its diameter. As a pre-condition for in vivo func-
ionality, preservation of structural integrity and function-
lity after the delivery procedure was evaluated in vitro in
EHV from a single source of ovine cells (n  4).
ELL HARVEST. Autologous myofibroblasts were harvested
rom ovine jugular veins as previously described (13).
ndothelial cells were harvested from ovine carotid arteries.
he myofibroblasts were expanded in Dulbecco’s Modified
agle Medium (DMEM) supplemented with 10% lamb
erum (Gibco, Invitrogen, Carlsbad, California), 1% Glu-
aMax (Gibco), and 0.1% gentamycin (Biochrom, Berlin,
ermany). The endothelial cells were cultured in endothe-
ial basal medium (EBM-2, complemented with 0.1%
ascular endothelial growth factor, 0.4% human fibroblasts
rowth factor, 0.1% human recombinant long–insulin-like
rowth factor-1, 0.1% human epidermal growth factor,
.1% gentamycin and amphotericin, 0.04% hydrocortisone,
.1% heparin, 0.1% ascorbic-acid [Cambrex, Verviers, Bel-
ium]) supplemented with 10% lamb serum. All animals
eceived humane care, and the study was approved by the
thics committee (IMM Recherche, Paris, France) and was
n compliance with the “Guide for the Care and Use of
aboratory Animals,” published by the National Institutes
f Health (NIH publication no. 85-23, revised 1985).
EART VALVE SCAFFOLD FABRICATION. Trileaflet heart
alve scaffolds (n  16), were fabricated from nonwoven
olyglycolic acid meshes (thickness 1.0 mm; specific gravity
0 mg/cm3; Cellon, Bereldange, Luxembourg), coated with
.75% poly-4-hydroxybutyrate (MW: 1  106; Tepha,
exington, Massachusetts) by dipping into a tetrahydrofu-
an solution (Fluka, Steinheim, Germany). After solvent
vaporation, physical bonding of adjacent fibers and contin-
ous coating was achieved. Poly-4-hydroxybutyrate is a
iologically derived rapidly degradable biopolymer, which
Figure 2 Crimping of TEHV for Transapical Delivery
The diameter was gradually reduced by a factor of 2.5 (A to D) before the tissue eesides being strong and pliable, is thermoplastic (61°C),
nd can be molded into 3-dimensional shapes. From the
olyglycolic acid/poly-4-hydroxybutyrate composite scaffold
aterial, the heart valve scaffolds were fabricated by using a
eat-application welding technique. Thereafter, the scaf-
olds were integrated into radially self-expandable nitinol
tents (length  38 mm, outer diameter [OD]  30 mm
hen fully expanded at 37°C; pfm AG, Köln, Germany) by
ttaching the scaffold matrix to the inner surface of the
itinol stent wires using single interrupted sutures (5-0
rolene, Ethicon, Somerville, New Jersey). After vacuum
rying overnight, the scaffolds were placed in 70% ethanol
Sigma, St. Louis, Missouri) for 4 h to obtain sterility. The
thanol was allowed to evaporate overnight, the scaffolds
ere washed in PBS (Sigma) and incubated overnight in
edium DMEM Advanced, supplemented with 2.5% lamb
erum, 1% GlutaMax, 0.3% gentamycin, and additional
-ascorbic acid 2-phosphate (0.25 mg/ml, Sigma), referred
o as TE-medium, to facilitate cell attachment by deposition
f proteins.
ELL SEEDING AND IN VITRO CULTURING OF TEHV. Seed-
ng of the myofibroblasts onto the stented heart valve
caffolds (1.5  0.04  106 cells/cm2) was performed using
brin as cell carrier (14). After seeding, the scaffolds were
laced into pulse duplicator systems, exposing the leaflets to
ncreasing dynamic strains, as previously described (15).
edium was replaced every 2 to 3 days. After 11 to 12 days,
he TEHV were seeded with endothelial cells (1.6  0.2 
05 cells/cm2) and cultured for 2 to 3 additional days (n 
2). For optimized surface coverage of the free edges, a
ubgroup of TEHV (n  4) was cultured for 6 additional
ays under the same dynamic straining and in addition flow
onditioning (nonpulsatile, low-pressure flow).
EHV DELIVERY PROCEDURES. After the in vitro culture
eriod, the OD was decreased from 30 mm to 10 mm
Fig. 2A to 2D) using a custom-built tubular-shaped
rimping and delivery system (Acrostak, Geneva, Swit-
ered heart valve (TEHV) was introduced into the implantation device.ngine
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August 3, 2010:510–20 Minimally-Invasive Autologous Tissue Engineered Heart Valveerland). The TEHV were left in the device for 30 min,
epresenting a clinically relevant time frame. Thereafter,
he TEHV were either implanted (n  6) or directly
nalyzed (n  5; 1 sample was excluded because of
echnical preservation problems).
N VITRO VALVE TESTING. The in vitro valve performance
f a TEHV after simulated delivery procedure was visual-
zed in a custom-built valve tester (16), using a high-speed
ideo camera (Phantom version 9.0, Vision Research,
ayne, New Jersey). The TEHV was exposed to physio-
ogical systemic flows for 20 min, and the resulting pressure
nd flow profiles were measured using flow (Transonic
ystems, Ithaca, New York) and pressure sensors (Becton
ickinson, Erembodegem, Belgium). The amount of re-
urgitation, the effective orifice area, and the mean and
aximal systolic pressure gradients were calculated and
veraged over 5 cycles.
EHV IMPLANTATION AND IN VIVO FUNCTIONALITY. For
valuation of in vivo functionality TEHV were minimally-
nvasively delivered into the pulmonary valve position using
n anterolateral-thoracic access and antegrade approach.
he valves were crimped and loaded onto a custom-made
nducing system (OD  12 mm) consisting of a rigid tube
nd pusher. After minithoracotomy and after pericardiot-
my, the right ventricle was punctured using needle through
ursestring sutures. Subsequently, the inducing system was
nserted, and the valve delivered into the pulmonary artery
nder visualization by fluoroscopy. After the optimal posi-
ion for the pulmonary heart valve replacement was defined
Figure 3 Delivery of the TEHV
Schematic view of transapical valve delivery (A) and positioning (B) in the pulmon
valve (TEHV) is inserted transapically into the right ventricle (a). The delivery syste
the nitinol stent (b) is carefully deployed into the pulmonary position by slowly advy angiography, the valve was pushed out of the delivery
ystem and allowed to open (Figs. 3A and 3B). Thereby, the
adial forces of the nitinol stent pressed the native heart
alve leaflets to the artery wall and kept them fixed.
fterward, the appropriate position and functionality of the
mplanted valve was visualized by angiography. Moreover,
he in vivo functionality was monitored using transthoracic
chocardiography during the procedure, immediately after
mplantation, and then weekly up to 8 weeks. Anticoagu-
ation therapy was maintained as in conventional biopros-
hetic heart valves for 7 days. The animals were sacrificed,
nd the TEHV were explanted after 4 weeks (n  3) and 7
o 8 weeks (n  3).
UALITATIVE TISSUE ANALYSES. The TEHV (n  16),
ither directly or after having functioned as implant, were
valuated macroscopically, and tissue composition was an-
lyzed qualitatively by immunohistology and compared with
ative valve leaflets. The tissue sections were studied by
ematoxylin and eosin staining for general tissue morphol-
gy, Masson-Trichrome staining for deposition of collagen,
nd Elastin van Gieson staining for detection of collagen
nd elastic fibers. Additionally, immunohistology was per-
ormed using the Ventana Benchmark automated staining
ystem (Ventana Medical Systems, Oro Valley, Arizona)
nd antibodies for -smooth muscle actin (-SMA [clone
A4, Sigma]) and von Willebrand factor (affinity purified
abbit antibodies, DakoCytomation, Copenhagen, Den-
ark). Primary antibodies were detected with the Ventana
VIEW DAB detection kit, yielding a brown reaction
sition. The delivery system loaded with the crimped tissue engineered heart
sists of an inner pusher (c) and a sheath (d). The crimped TEHV integrated into
the inner pusher (c) into the sheath system (d).ary po
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Minimally-Invasive Autologous Tissue Engineered Heart Valve August 3, 2010:510–20roduct. Furthermore, tissue samples were fixed in 2%
lutaraldehyde (Sigma) and sputtered with platin to exam-
ne the surface structure by scanning electron microscopy.
UANTITATIVE TISSUE ANALYSES. The TEHV used to
tudy the effect of the delivery procedure (n  2 uncrimped,
nd n  2 crimped), the explants (n  6) and their
orresponding control valves and native ovine valves (n 3)
ere analyzed by biochemical assays for total deoxyribonu-
leic acid (DNA) content, as an indicator for cell number,
lycosaminoglycans (GAG) content, and hydroxyproline
ontent, as an indicator for collagen. For measuring DNA
mount, the Hoechst dye method (17) was used with a
tandard curve prepared from calf thymus DNA (Sigma) in
ddition to the samples. The GAG content was determined
sing a modified version of the protocol described by
arndale et al. (18), and a standard curve was prepared from
hondroitin sulphate from shark cartilage (Sigma) in addi-
ion to the samples. Hydroxyproline was determined with a
odified version of the protocol provided by Huszar et al.
19), and a standard curve was prepared in addition to the
amples.
ECHANICAL PROPERTIES. The mechanical properties of
he leaflets were determined in circumferential and radial
irection by uniaxial tensile tests for the TEHV used to
tudy the effect of the delivery procedure (n  2 uncrimped,
nd n  2 crimped). Furthermore, in the explants, and the
orresponding control valves, thickness of the samples was
etermined with a PL 2300 optical imaging profiler
Sensofar-Tech S.L., Barcelona, Spain). Stress-strain curves
ere obtained using a uniaxial tensile tester (Kammrath &
eiss GmbH, Dortmund, Germany; load cell of 20N) with
constant strain rate of 1.7%/s. The ultimate tensile stress
UTS) was determined from the curves. The modulus of
lasticity (further referred to as modulus) was obtained from
he slope of the linear section of the stress-strain curve as an
ndicator for tissue stiffness.
xperimental study B: autologous stem cells as less
nvasive, multipotent cell source for minimally-invasive
EHV. In the second set of experiments, the focus was on
dult stem cells as autologous, noninvasive cell source. The
rincipal experimental design was comparable to study A.
owever, to accommodate the technology to this alternative
ell source, the cell harvest methodology and features as to
iodegradable scaffold material and in vitro culture protocols
ave been modified as follows.
ANDWICH-STRUCTURED HEART VALVE SCAFFOLDS.
hese scaffolds were fabricated from biodegradable P(L,DL)
A [Poly(L-lactide-co-D,L-lactide)] multifilament fibers us-
ng a 3-dimensional valve-shaped cast and thermal fixation.
hereafter, the surfaces were coated with P(L,DL)LA
ased nanofibers by electrospinning in order to produce a
ultilayer structure mimicking the architecture of native
eart valves. The P(L,DL)LA was dissolved in 1,1,1,3,3,3-
exafluoro-2-isopropanol and the polymer solution was tlectrospun onto the surfaces of the molded structure. The
esulting sandwich-structured heart valve scaffolds were
llowed to dry and were then sterilized by gamma irradia-
ion afterward. Finally, the scaffolds were integrated into
elf-expanding nitinol stents (OD  30 mm), as in exper-
mental study A.
ELL HARVEST, ISOLATION, AND SEEDING. Adult stem
ells were obtained from bone marrow as well as peripheral
lood of adult sheep (INRA Brouëssyand; ethical approval
o. Zurich-08-04, Switzerland). For the isolation of
yofibroblast-like cells, 20 ml bone marrow was aspirated
rom the iliac crest, and mononuclear cells were isolated
sing density gradient centrifugation (Histopaque-1077,
igma) (20). Cells were collected from the interphase and
ultured in DMEM (as described in study A) under
umidified incubator conditions (CO2 5%, 37°C). Endo-
helial progenitor cells were collected from 20 ml peripheral
lood, using the same density gradient and centrifugation as
escribed previously (21,22). Subsequently, cells were ex-
osed to endothelial basal medium (as described for study
) to enable endothelial cell differentiation.
According to study A, sandwich-structured trileaflet
eart valve scaffolds (n  4) were seeded with bone
arrow-derived myofibroblast-like cells using fibrin as a cell
arrier (14) and cultured under static conditions. After 6
ays, the heart valves were inserted into a flow-bioreactor
ystem (23) and exposed to pulsatile flow for 3 additional
ays followed by endothelialization using autologous pe-
ipheral blood-derived endothelial cells. After seeding, the
onstructs were kept under static conditions for 3 additional
ays to enable endothelial cell attachment and proliferation
n the valve surfaces.
EHV IMPLANTATION, IN VIVO FUNCTIONALITY, AND ANALYSES.
n vivo performance up to 4 weeks of TEHV (n  2) was
valuated in pulmonary position. Next to each implanted
EHV, an additional valve was engineered for each animal
o serve as a control valve (n  2). Minimally-invasive
mplantation procedures, assessment of TEHV functional-
ty and tissue analysis methodology was performed as in the
xperimental study A. In addition to the immunohistology
f study A, tissue sections were also stained for endothelial
itric oxide synthase (eNOS) type III (affinity purified
abbit antibodies; BD Biotechnology, Santa Cruz, Califor-
ia) with signal enhancement using the Ventana amplifica-
ion kit.
tatistical analysis of study A and study B. Quantitative
ata are presented as mean  SD of the mean. Student t
ests were used to determine the influence of the simulated
elivery procedure on TEHV properties, with each leaflet
eing considered as n 1. The use of the leaflets as the unit
f analysis was made without adjustment for correlated
bservations within individuals. All p values 0.05 were
onsidered statistically significant. The intersheep variability
id not allow for comparisons between time points. Fur-
hermore, results of vascular cell- and stem cell-based
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August 3, 2010:510–20 Minimally-Invasive Autologous Tissue Engineered Heart ValveEHV were not directly comparable because of method-
logical differences in fabrication.
esults
mpact of crimping on living TEHV. The impact of
rimping on the living TEHV was investigated in valves
enerated from vascular-derived cells (study A). The
EHV showed proper opening and closing behavior after
imulation of the delivery procedure when exposed to
ystemic conditions, with a regurgitation value of 8  3%.
he effective orifice area during systole was 1.9  0.1 cm2,
nd the mean and maximal pressure gradients during
iastole were 5.1  0.3 mm Hg and 17.6  0.3 mm Hg,
espectively (thereby fulfilling the International Organiza-
ion for Standardization 5840 guidelines for valvular re-
lacements of 29 mm).
Cellular tissue formation and abundant amounts of col-
agen were demonstrated in the leaflets (Figs. 4A and 4B)
nd the wall, with higher cellularity and collagen deposition
Figure 4 Histology of TEHV Leaflets on Basis of Vascular-Derive
Hematoxylin and eosin stain (A, E), Masson’s Trichrome stain (B, F), von Willebra
lated delivery, cellular tissues were demonstrated (A) with abundant amounts of c
leaflets. After simulated delivery, the leaflets demonstrated preserved structural in
valve (TEHV) was detected (G). Stem cell-derived TEHV leaflets (I to L): hematoxyl
leaflets (I) comparable to their native counterpart (M). Collagen production was as
detected in stem cells (K) but was absent in native interstitial valve cells (O). Mo
cell-based (L) as well as the native valvular leaflets (P), indicating the presence on the outer tissue layers. Elastin was not detected. Within
xperimental study A, no significant differences were found
n vitro and in vivo with regard to extracellular matrix
omposition, morphological structure, and mechanical
roperties in relation to the adapted in vitro conditioning
rotocol (that is subgroup including additional flow
onditioning).
After the delivery procedure, preserved cellularity, struc-
ure, and collagen deposition was demonstrated in the
eaflets (Figs. 4E to 4H) and the wall. Endothelial cells,
overing the luminal surfaces of the leaflets (Fig. 4C), were,
lthough incomplete, detectable after the simulated delivery
rocedure (Fig. 4G). Scanning electron microscopy pictures
f the hinge region and the leaflets, without simulated
elivery (Figs. 5A and 5C) and with simulated delivery
Figs. 5B and 5D) confirmed the preservation of structural
ntegrity after the delivery procedure.
Moreover, the delivery procedure induced no significant
issue damage resulting in cell loss as indicated by the
lls, Uncrimped and Crimped
tor stain (C, G), and -smooth muscle actin (SMA) staining (D, H). Before simu-
n in the outer layers (B) and endothelial coverage (C) at the luminal side of the
(E to H). However, incomplete endothelialization of the tissue engineered heart
eosin staining demonstrated a tissue architecture for adult stem cells based
lized by Masson’s Trichrome staining (J, N). The -SMA expression could be
endothelial nitric oxide synthase was expressed in the surface cells of the stem
dothelial layer.d Ce
nd fac
ollage
tegrity
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Minimally-Invasive Autologous Tissue Engineered Heart Valve August 3, 2010:510–20mount of DNA (3.4  0.2 g/mg uncrimped and 3.0 
.4 g/mg crimped), GAG (12.3  0.8 g/mg uncrimped
nd 11.4 1.2 g/mg crimped), and hydroxyproline (9.7
.6 g/mg uncrimped and 9.7  0.5 g/mg crimped). The
mount of DNA, GAG, and hydroxyproline of the TEHV
as lower compared with the amounts measured in native
vine leaflets (29%, 29%, and 17%, respectively). When
ormalized to the amount of DNA, it was noted that the
xtracellular matrix synthesis activity in the TEHV was
loser or even comparable to that in native ovine leaflets
hydroxyproline per DNA 61% and GAG per DNA 100%).
Comparable mechanical behavior was found for the radial
nd circumferential strips of the leaflets in both the crimped
nd uncrimped TEHV and further treated as 1 group. The
elivery procedure did not affect the modulus and UTS
Table 1).
n vivo performance of TEHV. The transapical implan-
ation procedures of study A and study B were uneventful in
ll animals (n  8) regarding perioperative morbidity or
ortality. Furthermore, all valves were deployed successfully
t the targeted site, demonstrated by fluoroscopy (Online
ideo 1, video fluoroscopy). No migration of the TEHV or
aravalvular leakage was observed. Proper opening and
losing behavior was demonstrated by transthoracic echo-
ardiographic measurements (Online Videos 2A and 2B). The
ntraoperative transthoracic echocardiogram revealed an initial
ean pressure gradient of 30 mm Hg, constantly decreasing
own to 10 mm Hg over the whole period of implantation
Figure 5 SEM of TEHV Leaflets Before and After Simulated Del
Scanning electron microscopy (SEM) of tissue engineered heart valve (TEHV) leafle
and the leaflets (C, D), demonstrated preserved tissue structure after simulated dime. Minimal regurgitation was detected in 2 animals, which
v
iemained unchanged over the whole period of implantation
ime.
Macroscopic analysis of all explanted valve leaflets, demon-
trated thickened tissue formation (Fig. 6). The wall of the
EHV was integrated into the adjacent tissue. Dense, layered
issue with thickened outer layers, containing abundant
mounts of collagen, was demonstrated (Figs. 7B and 7E). No
lastin was detected. Cells staining positive for -SMA were
dentified mainly in the wall of the explanted valves, but also in
he middle of the leaflets (Figs. 7D and 7G). In some areas, a
eposition of fibrinous material was detected.
Quantitative tissue analyses for the amounts of DNA,
AG, and hydroxyproline of all explanted valve leaflets,
xpressed in percentages to native valve leaflets, are sum-
arized in Table 2. Note that the quantitative results of the
Procedure
owing the hinge region (A, B)
(B, D).
iomechanical Properties of Crimped, Uncrimped,nd Expl ted Vascular Cell- and Stemell-Based TEH
Table 1
Biome hanical Properti s of Cri ped, Uncrimped,
and Explanted Vascular Cell- and Stem
Cell-Based TEHV
Modulus (MPa) UTS (MPa)
Vascular cell-based TEHV
Crimped TEHV (n  2) 3.09 0.49 0.60 0.13
Uncrimped TEHV (n  2) 3.08 0.56 0.54 0.08
Explanted TEHV, 4 weeks (n  3) 0.83 0.70 0.27 0.22
Explanted TEHV, 8 weeks (n  3) 2.20 4.10 1.01 2.17
Stem cell-based*
Explanted TEHV – 4 weeks (n  2) 0.63 0.15 0.27 0.06
ean values and standard deviations for modulus (indicating elasticity) and ultimate tensile
trength (UTS) in megapascal (MPa). *Results of adult stem cell-based tissue engineered heartivery
ts, sh
eliveryalve (TEHV) are not directly comparable to vascular cell-based TEHV because of the methodolog-
cal differences in fabrication.
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August 3, 2010:510–20 Minimally-Invasive Autologous Tissue Engineered Heart Valvetem cell-based TEHV (experimental study B) are not
irectly comparable to the vascular cell-based TEHV be-
ause of the principal methodological difference between
tudies A and B (see also the Methods section). The
mounts of DNA, GAG, and hydroxyproline present in the
xplants appeared equal or increased when compared with
heir corresponding controls for the vascular cell-based
EHV.
utologous stem cell-based minimally-invasive TEHV.
dult stem cells were isolated from bone marrow as well as
eripheral blood and demonstrated growth characteristics
omparable to those of vascular cells, resulting in sufficient
uantity for seeding at passage 3. Bone marrow-derived
ells cultured in fibroblast-inducing medium showed a
yofibroblast-like phenotype expressing -SMA. Periph-
ral blood-derived endothelial progenitor cells exposed to
ndothelial medium formed cobblestone-like monolayers
nd showed endothelial characteristics similar to previous
tudies (10,22).
After the seeding and in vitro culture process, all valves
acroscopically demonstrated excellent tissue formation.
istology of valves revealed cell attachment and ingrowth as
bserved in hematoxylin and eosin staining (Fig. 4I). Com-
ared to cross-sections of native heart valves (Fig. 4M),
ngineered leaflets were thicker than their native counter-
arts, similar to the vascular-cell based TEHV, due to the
nitial thickness of the scaffold material. Collagen fibers
ere predominantly present in the outer layers as visualized
y Masson’s Trichrome staining (Fig. 4J) and comparable to
he distribution pattern in native leaflets (Fig. 4N). Cells in
he newly formed tissues expressed -SMA (Figs. 4D, 4H,
nd 4K), whereas native interstitial valve cells did not
Fig. 4O). On the surfaces of the TEHV leaflets, eNOS
xpression could be detected as well as on the native valve
eaflets, indicating the presence of an endothelial layer
Figure 6 Macroscopic Appearance of Explanted TEHV
Representative photographs of the leaflets and wall of an explanted tissue engineFigs. 4L and 4P). eValve functionality with leaflet movement and sufficient
pening and closing behavior was observed after implanta-
ion. No paravalvular leakage could be detected in the
ollow-up controls.
Hematoxylin and eosin staining of explants demonstrated
ayered tissues without indication for the foreign body
eaction. An example of an explanted leaflet based on adult
tem cells is shown in Figure 7A. Masson’s Trichrome
taining confirmed the presence of collagen predominantly
n the outer layers (Fig. 7B). Cells of the leaflet surface layer
xpressed apart from eNOS (Fig. 7C) also -SMA (Fig. 7D),
esembling the staining pattern of native valve endothelial cells.
oreover, -SMA expression could be detected in interstitial
ells of the newly formed tissue and was lower in explanted
EHV leaflets. The modulus of the valve leaflets was de-
reased after 4 weeks in vivo.
iscussion
inimally-invasive techniques have recently shown to be
romising alternatives to conventional heart valve surgery
2,24,25). However, because the currently used replacement
aterials are bioprosthetic, it is likely that they are associ-
ted with calcification (26), leading to dysfunctionality as
as been observed for conventional valves (27). Living
utologous TEHV, based on rapidly degrading polymer
caffolds, and minimally-invasive valve replacement proce-
ures represent promising technologies for patients with
alvular heart disease.
This paper presents the first “proof of principle” in vivo
ata with regard to the combination of the novel technol-
gies tissue engineering including stem cells and minimally-
nvasive implantation. In particular, the use of autologous
tem cells might enable a truly minimally-invasive autolo-
ous valve replacement, from cell harvest to implantation. In
ummary, autologous TEHV, integrated into self-
eart valve (TEHV) after 4 weeks, (A) distal view and (B) proximal view.ered hxpandable stents, were developed and tested in vitro for
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Minimally-Invasive Autologous Tissue Engineered Heart Valve August 3, 2010:510–20reservation of structural integrity after the delivery proce-
ure before they were transapically implanted in the pul-
onary position of sheep. Delivery and deployment of the
EHV were demonstrated to be safe as all procedures were
neventful. The living TEHV demonstrated adequate func-
ionality, but thickened leaflets.
The application of the TEHV for transapical delivery
equired the valve to be integrated into a stent. As a
linically established concept, nitinol stents were chosen as
hey possess shape memory, are self-expanding, and in
ontrast to balloon-expandable stents, allow the least de-
tructive expansion of the delicate living TEHV. The heart
alve design included a vascular wall for prevention of
aravalvular leakage and to protect the leaflets from damage
y the stent struts during the crimping and delivery proce-
Figure 7 Histology of Explanted TEHV Leaflets on Basis of Adu
Adult stem cell-based tissue engineered heart valve (TEHV): the explanted tissues
Masson’s Trichrome staining, collagen fibers were predominantly found in the oute
thase (C) and -smooth muscle actin (SMA) (D). Moreover, -SMA expression cou
scaffold material. Vascular cell-based TEHV: a compilation of several pictures is co
tissue formation with abundant amounts of collagen (E) and no elastin (F). Active
lets (G).ure (28). Aiming at an autologous approach, vascular cells aere utilized as they have proven to be successful for heart
alve tissue engineering (8,13). The transapical delivery
equired crimping of the TEHV by a ratio of approximately
.5 compared with the original diameter, which is similar to
he crimping ratio clinically in stented bioprosthetic valves
2). In vitro simulation of the delivery procedure revealed
roper valve functioning and preserved structural integrity
nd no detectable damage to the leaflets and the wall.
lthough incomplete endothelialization of the TEHV was
een as a possible indicator of surface friction, in the absence
f any thromboembolic event, this appeared to be of no
linical relevance. The simulation of the delivery procedure
id not alter the mechanical properties as determined by
ensile tests.
Morphological analyses of the explanted leaflets based on
m Cells and Vascular-Derived Cells
d layered tissue architecture visualized by hematoxylin and eosin staining (A). In
e layer (B). Cells of the surface layer expressed endothelial nitric oxide syn-
detected in subpopulations of the inner layer (D). Arrows indicate reminiscent
d to a microscopical map of part of a TEHV leaflet. These pictures show layered
A expressing myofibroblasts were located only in the middle layer of the leaf-lt Ste
showe
r tissu
ld be
mbine
-SMutologous vascular cells demonstrated thickened and lay-
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emodeling process, as in previous studies, the initially
hickened leaflets were shown to fully remodel to thin
ative-like leaflets beyond 8 to 12 weeks (8). The tissue
ngineered wall structures were integrated into the adjacent
ative tissue for all explanted valves. Interestingly, it seemed
hat the increased extracellular matrix deposition in the
xplanted vascular cell-based TEHV was mainly due to
AG deposition. This observation is in accordance with
arly development in fetal heart valves (29), indicating that
he remodeling process of the TEHV after 8 weeks may still
e in an early developmental stage. The observed deposition
f fibrinous material on the valve surfaces might have been
nduced by the compromised endothelial properties. Further
n-depth studies are necessary to unravel the biological
echanisms behind the thickening of the implanted TEHV
s well as the potential role of the partial lack of endothelial
ells in the remodeling process.
As in previous tissue engineering studies, no relevant
mounts of elastin were detectable in the engineered valve
issues by quantitative analysis. This was also reflected by
he measured reduced pliability of the engineered heart
alves and represents a concern with regard to the long-term
unctionality of the engineered valves in particular with
egard to future systemic use. To address this limitation,
mproved in vitro protocols are under investigation specifi-
ally focusing on accelerated elastin formation and exploring
arious stimulation protocols, such as hypoxia (30).
Aiming at minimal invasiveness also with respect to cell
arvest, preliminary in vitro and in vivo experiments with
utologous living TEHV based on adult stem cells were
erformed in the second set of experiments. Functional
eart valves were successfully fabricated from myofibroblast-
ike cells isolated from bone marrow aspirates and peripheral
lood-derived endothelial cells seeded onto sandwich-
tructured scaffolds. Successful endothelialization of heart
alve surfaces before implantation using peripheral blood-
erived endothelial progenitor cells could be demonstrated.
n the leaflet surfaces, differentiated peripheral blood-
erived endothelial progenitor cells demonstrated pheno-
ypes comparable to native valve endothelial cells as indi-
uantitative Tissue Analysis of Explanted TEHVn Basis of Va c lar-Derived Cells and Stem CellsTable 2 Quantitative T su An lysis of Exp anted TEHVon Basis of Vascular-Derived Cells and Stem Cells
DNA
(% Native
Leaflets)
GAG
(% Native
Leaflets)
Hyp
(% Native
Leaflets)
Vascular cell-based TEHV
4 weeks (n  3) 49 24 39 9 15 6
8 weeks (n  3) 44 18 39 6 18 3
Adult stem cell-based TEHV*
4 weeks (n  2) 86 54 150 11 26 6
Results of adult stem cell-based tissue engineered heart valves (TEHV) are not directly compara-
le to vascular cell-based TEHV because of the methodological differences in fabrication. Mean
mounts and standard deviations of glycosaminoglycans (GAG), deoxyribonucleic acid (DNA), and
ydroxyproline (Hyp) expressed in percentage to native valve leaflets.ated by the co-expression of eNOS and -SMA (31). (hese data suggest peripheral blood as a promising source
or engineering native-analogous endothelia. Finally, the
uccessful minimally-invasive implantation of these heart
alves was demonstrated in this feasibility study. Thus,
he use of these 2 easy-to-access adult stem cell sources
bone marrow and peripheral blood) realizes a complete
inimally-invasive (nonsurgical) cell harvest protocol for
utologous heart valve tissue engineering that could be easily
ntegrated into routine ambulant clinical procedures.
Although based on the same principal concept, the
resented data in fact reflect a certain evolution/progress
ith regard to details of the involved methodologies. In
articular, the biodegradable scaffold material and design of
tudy A (feasibility) was modified and further developed for
he specific use of stem cells in study B. In contrast to a less
tructured (mesh structure, study A), a layered (sandwich)
esign was used in study B, mimicking the 3-layered
tructure of a natural heart valve and thereby providing a
ore “biologically inspired” microenvironment to the cells.
his inherently implies a limitation as to direct comparisons
etween the 2 study groups.
Further studies are mandatory to elucidate the long-term
ate of such living engineered heart valves after minimal
nvasive delivery as well as the underlying tissue remodeling
echanisms observed in vivo. Particularly, the role of the
eeded cells with respect to their origin and state of
ifferentiation has to be systematically assessed by, for
xample, cell-tracking methodology, also to validate
hether seeded cells persist in neotissues and contribute to
issue remodeling (32). However, addressing these questions
as beyond the scope of this pilot study and will be
nvestigated in future experiments.
onclusions
hese first results of combining minimally-invasive valve
eplacement procedures with tissue engineering are prom-
sing and demonstrate the feasibility of merging the current
hot topics” in heart valve replacement technologies. More-
ver, when combined with minimally-invasively harvested
utologous adult stem cells, a clinically relevant complete
inimally-invasive concept may be realized. Although rep-
esenting only a first in vivo investigation revealing chal-
enging questions, process safety has been demonstrated,
nd future studies have been initiated to assess long-term in
ivo functionality as well as a completely transvascular
atheter-based delivery approach.
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